Avidity Biosciences (NASDAQ:RNA) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Avidity Biosciences (RNA) operate in?

Avidity Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Avidity Biosciences Stock (NASDAQ: RNA) stock price, news, charts, stock research, profile.

Open	-
Close	-
Volume / Avg.	0 / 1.31M
Day Range	- - -
52 Wk Range	5.68 - 56.00
Market Cap	$5.93B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	53
Short Interest	15.33%
Days to Cover	19.95

Recent News

Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases

Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing multi-blockbuster commercial opportunities for its RNA therapeutics in muscular dystrophies.

Vandana Singh

Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease

BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in the study's success.

Vandana Singh

Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Jun

Aug

Sep

Oct

Nov

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	0 / 1.31M
Day Range	- - -
52 Wk Range	5.68 - 56.00
Market Cap	$5.93B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	53
Short Interest	15.33%
Days to Cover	19.95

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Avidity Biosciences (RNA) stock?

You can purchase shares of Avidity Biosciences (NASDAQ:RNA) through any online brokerage.

View our list of the best stock brokerages

Who are Avidity Biosciences (RNA) competitors?

Other companies in Avidity Biosciences’s space includes: Legend Biotech (NASDAQ:LEGN), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS) and Ionis Pharmaceuticals (NASDAQ:IONS).

What is the forecast, or price target, for Avidity Biosciences (RNA) stock?

Avidity Biosciences has a consensus price target of $56.92.

What is the current price for Avidity Biosciences (RNA)?

The stock price for Avidity Biosciences (NASDAQ: RNA) is $50.2 last updated November 14, 2024 at 6:35 PM EST.

Does Avidity Biosciences (RNA) pay a dividend?

There are no upcoming dividends for Avidity Biosciences.

When is Avidity Biosciences (NASDAQ:RNA) reporting earnings?

Avidity Biosciences’s Q3 earnings are confirmed for Thursday, November 7, 2024.

Is Avidity Biosciences (RNA) going to split?

There is no upcoming split for Avidity Biosciences.

What sector and industry does Avidity Biosciences (RNA) operate in?

Avidity Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Avidity Biosciences

Avidity Biosciences (RNA) Forecast